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Abstract The p21-activated kinase, Pak, has recently been
shown to phosphorylate Raf-1 on serine 338 (S338), a critical
regulatory residue. The specificity requirements for Pak-
mediated phosphorylation of S338 were examined by substitution
analysis of Raf-1 peptides and conserved region 3 (CR3)
proteins. Phosphorylation was found to be very sensitive to
alterations in amino acid side chains proximal to S338. Loss of
N-terminal arginines resulted in decreased peptide phosphoryla-
tion while loss of these residues, as well as C-terminal glutamates
and bulky C-terminal hydrophobic residues, decreased phosphor-
ylation of the CR3 protein. Phosphorylation of Raf-1 on tyrosine
341 is significant in epidermal growth factor- and Src-mediated
signaling, suggesting that cooperativity may exist between Pak
and Src phosphorylation of Raf-1. Purified Pak and Src were
found not to be cooperative in phosphorylating peptides or
purified CR3 protein. However, the phosphorylation of Raf-1
S338 by Pak was increased in the presence of Src. The
complexity of this signaling module could thus account for the
different levels of Raf-1 activation required for fulfillment of
different biological roles within the cell. ß 2001 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
Regulation of the Raf-1 protein kinase is complex and in-
volves many protein interactions and post-translational mod-
i¢cations [1]. Following exchange of GTP for GDP the mem-
brane-associated GTPase, Ras, recruits Raf-1 to the plasma
membrane [2]. Raf-1 then undergoes a number of changes in
phosphorylation state and protein interactions [3^6]. Major
sites of phosphorylation on Raf-1 are serines 43, 259 and
621 [7,8]. A number of recent studies have demonstrated
that phosphorylation of serine 338 (S338) and tyrosine 341
(Y341) are critical for mitogenic signaling in response to cer-
tain stimuli [2,9^12]. The proximity of these two sites has
suggested that cooperativity may exist between the two pro-
tein kinases responsible for phosphorylating this region [6,12].
While tyrosine phosphorylation has been studied in the con-
text of Src, we recently demonstrated the p21-activated kinase,
Pak3, as capable of phosphorylating S338 [13]. We have sub-
sequently extended this observation to Pak1 and Pak2 (un-
published data). This observation linked another signaling
pathway into the complex regulatory mechanism of Raf-1
activation, namely that acting through phosphatidylinositol
3-kinase, Dbl-family guanine nucleotide exchange factors
and Cdc42/Rac [14,15].
While the regulation and activity of the p21-activated ki-
nases in biological systems are complex matters in their own
right [16], some studies have examined the substrate speci¢city
of these kinases. Pak2 has been shown to phosphorylate intact
endothelial cell non-muscle myosin II and isolated recombi-
nant myosin regulatory light chains, but not myosin heavy
chains [17]. This phosphorylation is dependent upon the pres-
ence of arginine at the P33 position. Interestingly, the myosin
I heavy chain kinase has been shown to be a distinct Pak-
family kinase [18] and phosphorylates myosin I heavy chains
in a manner similar to that observed for Pak1 [19]. Substrate
speci¢city of Pak2 has been examined by substitution analysis
of peptides based on the Rous sarcoma virus nucleocapsid
protein sequence KKRKSGL [20]. This group found a re-
quirement for basic amino acids in the P32 and P33 posi-
tions, quoting the optimal minimal sequence as (K/R)RXS,
where X is any acidic, basic or neutral amino acid. Acidic
or basic amino acids at P31 and P34 increase the e⁄ciency
of phosphorylation, while proline at P31 or P+1 diminishes
this activity. Basic residues have also been implicated in Pak1
speci¢city [21]. Arginines at P33 to P35 and especially at
P+2 in the ribosomal protein S6 peptide 229^244
(AKRRRLSSLRASTSKS) are essential for e⁄cient phos-
phorylation of serine 236. Substitution of serine 235 dramat-
ically raises the Km, indicating sensitivity to proximal residues.
In this study we examined the substrate site speci¢city of
Pak centered on Raf-1 S338. In addition, the extent of coop-
erativity was measured between Pak and Src in the phosphor-
ylation of the Raf-1 S338Y341 site. Direct and indirect mech-
anisms of cooperation were examined in cells as well as in
vitro using puri¢ed proteins.
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2. Materials and methods
2.1. DNA constructs and proteins
Constitutively active (F91S, G93A, P95A) and dominant-negative
(K297R) hemagglutinin (HA)-tagged murine Pak3 constructs in pJ3H
were gifts of S. Bagrodia and R.A. Cerione. Constitutively active Src
(Y527F) in pECE-A was supplied by G.S. Feng and dominant-neg-
ative Src (K296R, Y528F) in pUSEamp was purchased from Upstate
Biotechnology (Lake Placid, NY, USA). Human cRaf-1, cloned into
pEXV-3 with an N-terminal FLAG-epitope tag, was generously pro-
vided by T.W. Sturgill. The Promega (Madison, WI, USA) Altered
Sites pALTER vector was used for mutagenesis of human Raf-1 con-
served region 3 (CR3; residues 307^648) as per the manufacturer’s
protocol. Mutants were then excised with EcoRI and XhoI and sub-
cloned into the Stratagene (La Jolla, CA, USA) pCal-n vector for
expression in BL21 (pLysS DE3) as N-terminal calmodulin-binding
peptide fusion proteins (CBP^CR3). Proteins were induced at 30‡C
with 0.5 mM isopropyl-L-D-thiogalactoside and recovered using the
manufacturer’s protocol. Histidine-tagged mouse Pak3 was prepared
from Sf9 cells and was kindly provided by S. Bagrodia and R.A.
Cerione.
2.2. Cell culture, transfection and lysis
COS-7 cells were maintained in Dulbecco’s modi¢cation of Eagle’s
medium (DMEM) with high glucose (Biowhittaker, Walkersville,
MD, USA) and supplemented with 5% fetal calf serum, 5% calf se-
rum, sodium pyruvate, L-glutamine and penicillin^streptomycin. Cells
were grown in 10% carbon dioxide at 37‡C. Cells were transfected by
electroporation with 10 Wg of each construct, as described elsewhere
[22]. Blank pEXV-3 vector and sheared salmon sperm DNA were used
as controls. Cells were harvested on the third day after transfection by
lysis in 50 mM Tris^HCl, 50 mM L-glycerophosphate, 1 mM sodium
orthovanadate, 10% glycerol, 1% Triton X-100, 1 mM EDTA, 1 mM
phenylmethylsulfonyl £uoride (PMSF), 1 Wg/ml each of aprotinin,
leupeptin and pepstatin A, pH 8. Lysates were aspirated through a
25-gauge needle four times and cell debris was pelleted by centrifuga-
tion at 100 000Ug, 4‡C for 15 min. HA-tagged Pak was immunopre-
cipitated from cells lysed in bu¡er (above) for 20 min on ice. Immu-
noprecipitations were performed at 4‡C with 2-h primary antibody
incubations followed by 1 h with Gamma-Bind Plus Sepharose beads
(Pharmacia, Piscataway, NJ, USA). Immunoprecipitates were washed
three times with lysis bu¡er and once with kinase assay bu¡er prior to
assay. Constitutively active Src (Y527F) was recovered from Src-
transformed Rat2 ¢broblasts, generously provided by G.S. Feng.
Src was immunoprecipitated with an anti-Src antibody (Santa Cruz,
CA, USA), washed three times with RIPA bu¡er and once with ki-
nase bu¡er prior to assay.
2.3. Kinase assays
Raf-1 kinase activity in anti-FLAG immunoprecipitates was mea-
sured by a coupled-kinase method described by Stokoe et al. [23].
Activities were normalized to the level of FLAG-Raf-1 present in
each immunoprecipitate determined by anti-FLAG Western blotting
of the primary incubations. In vitro kinase assays used a Raf-1 pep-
tide or CBP^CR3 substrates. Peptides corresponding to wild type or
substituted Raf-1 residues 331^345 (Table 1) were incubated at ¢nal
concentrations of 500 WM with recombinant Pak3, or active Src, in
the presence of 500 WM ATP, containing 4^6 WCi [Q-32P]ATP, at 30‡C
for 15 min. Incubations were then spotted onto P-81 phosphocellulose
papers (Whatman, Fair¢eld, NJ, USA). The P-81 papers were washed
repeatedly in 75 mM phosphoric acid, once in acetone, air-dried and
counted in 5 ml of liquid scintillant. Wild type and mutant CBP^CR3
proteins (V1 Wg each, see Table 1) were incubated with recombinant
Pak3 in the presence of 500 WM ATP, containing 6^10 WCi [Q-
32P]ATP, at 30‡C for 20 min. Incubations were resolved by SDS^
PAGE and transferred to Immobilon-P (Millipore, Bedford, MA,
USA). Membranes were then stained with 0.25% Ponceau S in 5%
acetic acid, dried and autoradiographed with Hyper¢lm-MP (Amer-
sham, Piscataway, NJ, USA). Radiolabeled bands were aligned with
stained protein bands to verify phosphorylation of CBP^CR3 and
levels of phosphorylation were measured by densitometric scanning
of autoradiographs as above.
Pak3 kinase activity was determined from duplicate HA-Pak3 im-
munoprecipitations from transfected cells. Immunoprecipitates were
washed, on ice, three times with lysis bu¡er and once with assay bu¡er
(20 mM HEPES, pH 7.4, 10 mM MgCl2, 0.5 mM EGTA, 0.02% Brij
35 and 0.5% L-mercaptoethanol). The immunoprecipitates were then
incubated in assay bu¡er containing 500 WM ATP, 10 WCi [Q-32P]ATP
and 500 WM Raf-1 peptide substrate, for 30 min at 30‡C. Reactions
were terminated by transferring onto P-81 ¢lter paper as described
above and radioactivity associated with the dried ¢lters was deter-
mined by scintillation counting.
2.4. Western blotting
Western blotting was used to quantitate the presence of Raf-1 in
immunoprecipitates, using an anti-FLAG antibody (mAb M2, Ko-
dak/Sigma, St. Louis, MO, USA). Pak protein expression was veri¢ed
using an anti-HA antibody (Santa Cruz). Neither Src construct was
tagged, but expression was con¢rmed by blotting with anti-Src (Santa
Cruz) to show increased levels of expressed Src protein in lysates.
Phosphorylation of Raf-1 on S338, or S338 and Y341 together, was
visualized by immunoprecipitation with phospho-speci¢c antisera (Re-
search Genetics, Huntsvillle, AL, USA) followed by immunoblotting
with anti-FLAG antibody. Values from densitometric scanning of
these blots corresponding to FLAG-Raf-1 were then normalized for
total FLAG-Raf-1 expression with densitometer readings from paral-
lel anti-FLAG blots of cell lysates.
3. Results
3.1. Phosphorylation of Raf-1 peptides
Synthetic peptides corresponding to Raf-1 residues 331^345
were used as substrates for Pak3. In addition to the wild type,
a range of substituted peptides was generated (Table 1). Se-
lected residues were altered to remove phosphorylation sites,
charges, reduce side chain steric constraints or mimic prior
phosphorylation by substitution with acidic residues (Fig.
1A). Dual substitution of S338/S339 with either alanine or
acidic residues obliterated the ability of Pak3 to phosphory-
late the substrate in agreement with our previous cell culture
data [13]. Dual substitution of Y340/Y341 with phenylalanine
resulted in only a marginal reduction in peptide phosphoryla-
tion. Substitution of aromatic residues 340^342 with alanines
increased peptide phosphorylation by Pak3 by about 30%,
which may result from S338 being more sterically accessible
to the kinase. Substitution of Y340/Y341 with aspartates,
Table 1
Substitutions in Raf-1 examined in this study
Substitution Type




S338A, S339A -------AA------ PKO
Y340F ---------F----- PKO
Y341F ----------F---- PKO
Y340F, Y341F ---------FF---- PKO
S338D -------D------- PM
S339D --------D------ PM
S338D, S339E -------DE------ PM
Y340D ---------D----- PM
Y341D ----------D---- PM
Y340D, Y341D ---------DD---- PM
D337N ------N-------- CKO
R336Q -----Q--------- CKO
R333Q, R336Q --Q--Q--------- CKO
R333Q, R336Q, D337N --Q--QN-------- CKO
E343Q, E345Q ------------Q-Q CKO
W342A -----------A--- SKO
Y340A, Y341A ---------AA---- SKO
Y340A, Y341A, W342A ---------AAA--- SKO
Each substitution is listed with a designated function. Key: PKO,
phosphorylation site knock-out; PM, phosphorylation mimetic;
CKO, charged residue knock-out; SKO, steric residue knock-out.
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mimicking prior phosphorylation, had a negative e¡ect
(s 60% decrease) on S338 phosphorylation. This might imply
that the presence of negative charges in close C-terminal prox-
imity to S338 is unfavorable to phosphorylation by Pak3.
Substitution of E343 and E345 with glutamine was inconse-
quential to Pak phosphorylation. However, single glutamine
substitution of R336 decreased Pak3-mediated phosphoryla-
tion (V30%), while dual glutamine substitution of R333 and
R336 decreased peptide phosphorylation s 80%. Similar re-
sults were obtained with Pak1 and Pak2 (unpublished data).
In contrast to Pak3, immunoprecipitated active Src demon-
strated di¡erent substrate requirements within the Raf-1 pep-
tide. Src was shown to be speci¢c for Y341 (Fig. 1B), as has
been reported elsewhere [12]. Substitution of Y341 with phe-
nylalanine abrogated Src-mediated peptide phosphorylation,
while tyrosine substitution of Y340 had little e¡ect. Addition-
ally, Src displayed a di¡erent preference for charged residues
£anking the Y341 phosphorylation site. Loss of the positive
charges at R333 and R336 had little e¡ect on Src phosphor-
ylation of the peptide. However, substitution of E343 and
E345 with glutamine decreased Src phosphorylation of Y341
approximately 40%. This agrees with the general speci¢city of
Src family kinases for phosphorylation sites £anked by acidic
residues. Substitution of S338S339 with acidic residues caused
a modest, yet signi¢cant, 40% increase in phosphorylation by
Src. This result raises the possibility that prior phosphoryla-
tion of S338 might enhance the ability of Src to phosphorylate
Y341. Finally, the speci¢city of Raf-1 peptide phosphoryla-
tion by puri¢ed Pak3 and Src was con¢rmed by phosphoami-
no acid analysis [24] of phosphorylated wild type, S338A and
Y341F peptides (Fig. 1C).
3.2. Phosphorylation of Raf-1 CR3 proteins
The Raf-1 CR3 domain represents a more structurally con-
strained substrate with which to study Pak substrate recogni-
tion requirements. Having observed the importance of charges
in the peptide, CR3 mutants were generated to test these ob-
servations further (Table 1). The relative phosphorylation of
CR3 proteins by Pak3 is shown in Fig. 2. What became ap-
parent was that phosphorylation of S338 is exquisitely sensi-
tive to side chain alterations in residues close to S338, includ-
ing substitution of S338 with threonine. In contrast to the
peptide results, loss of aromatic side chains at 340, 341 and
342 resulted in greatly decreased CR3 phosphorylation by
Pak3. This e¡ect was greater for residues closer to S338,
wherein W342A exhibited the least e¡ect. Interestingly, sub-
stitution of Y340 with aspartic acid all but eliminated S338
phosphorylation while substitution of Y341 with aspartic acid
was well tolerated. This result predicts that Pak should be able
to phosphorylate S338 in the presence of phosphorylated
Y341. The presence of a proximal negative charge at position
339 (S339D) was detrimental to peptide phosphorylation.
Charged residues were again signi¢cant in determination of
Pak3-mediated phosphorylation e⁄ciency. Substitution of ei-
ther R333/R336 or E343/E345 with glutamines had a negative
e¡ect on S338 phosphorylation. As with the peptides, R333
and R336 were found to be essential, with D337 being rela-
tively unimportant, in directing Pak3 phosphorylation of
S338. In contrast to the peptide results, the presence of neg-
atively charged residues at 343 and 345 was required for phos-
phorylation.
3.3. Pak and Src show synergy in Raf-1 activation
Cooperativity between Pak3 and Src was studied in transi-
ently transfected COS-7 cells where Raf-1 activation and
phosphorylation in vivo were monitored. Raf-1 activity was
measured from COS-7 cell lysates following co-transfection
with combinations of Pak3 and Src. Combinations of consti-
Fig. 2. Phosphorylation of CBP^CR3 fusion proteins by Pak3. Wild type or substituted CBP^CR3 proteins (V1 Wg each) were incubated with
recombinant Pak3 in the presence of 500 WM ATP, containing 6^10 WCi [Q-32P]ATP, at 30‡C for 20 min. Results shown are the means of at
least four separate experiments.
Fig. 1. Phosphorylation of Raf-1 synthetic peptides by Pak3 and Src. Peptides corresponding to wild type or substituted Raf-1 residues 331^
345 (see Table 1) were incubated at ¢nal concentrations of 500 WM with (A) recombinant Pak3 or (B) active Src, immunoprecipitated from S7a
cells, in the presence of 500 WM ATP, containing 4^6 WCi [Q-32P]ATP, at 30‡C for 15 min. Results are the means of at least four separate ex-
periments. Phosphoamino acid analysis showed site and residue type speci¢city of Pak3 and Src kinases with respect to Raf-1 peptides (C). Re-
combinant Pak3 or immunoprecipitated active Src were used to phosphorylate Raf-1 peptides; wild type (WT), S338A, Y341F. Broken ovals
indicate the positions of non-radiolabeled phosphoamino acid standards.
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tutively active Pak3 (Pakca) or Src (Srcca), or dominant-neg-
ative Pak3 (Pakdn) or Src (Srcdn) were examined for their
e¡ects on Raf-1 activation. While either Pakca or Srcca was
individually capable of eliciting Raf-1 activation, a coopera-
tive e¡ect of Pakca and Srcca was observed when the kinases
were presented together. Moreover, Raf-1 activation by Srcca
alone was greater than that achieved by Pakca alone. Expres-
sion of Srcca and Pakca together resulted in a further increase
in Raf-1 activation, illustrating potential cooperativity be-
tween the two kinases. Expression of dominant-negative Src
did not signi¢cantly diminish Raf-1 activation by Pakca nor
did dominant-negative Pak reduce Srcca activation of Raf-1.
This result suggests that phosphorylation of either S338 or
Y341 alone is su⁄cient to modulate Raf-1 activity, although
the degree of activation elicited by each respective phosphor-
ylation di¡ers by more than an order of magnitude.
3.4. E¡ect of prior phosphorylation on Pak3 and Src activities
The COS-7 cell experiments suggested that cooperativity
may occur between Pak and Src in Raf-1 activation. This
could be explained by S338 phosphorylation increasing Src-
mediated phosphorylation of Y341 (as suggested by the pep-
tide experiments), or by the sum of the mechanistic contribu-
tions of each phosphorylation. We returned to in vitro experi-
ments using Raf-1 peptides corresponding to residues 331^345
to address the question of whether the presence of a phos-
phate at Y341 or S338 could in£uence phosphorylation of the
peptide by Pak3 or Src, respectively. Raf-1 331^345 peptides
were synthesized containing either phospho-S338 or phospho-
Y341. The presence of a phosphate at S338 or Y341 resulted
in the loss of signi¢cant substrate phosphorylation by Pak3 or
Src, respectively (Fig. 3B). However, the consequence of hav-
ing an adjacent phospho-serine did not enhance Y431 phos-
phorylation by Src nor did the presence of phospho-Y341
enhance S338 phosphorylation by Pak3. This result suggests
that while the presence of adjacent phosphoamino acids is
compatible with additional phosphorylation of the 338/341
region by Src or Pak, the additional negative charge does
Fig. 3. Study of the potential for Pak3 and Src to cooperate in Raf-1 activation and phosphorylation. A: Analysis of the activation of Raf-1
in COS-7 cells by di¡erent combinations of Pak3 and Src constructs. COS-7 cells were transiently transfected with FLAG-tagged Raf-1 and dif-
ferent Pak3 and Src constructs. Cells were harvested 3 days later, Raf-1 was immunoprecipitated and immune complexes were assayed for ki-
nase activity in a coupled assay. B: Examination of the e¡ect of prior phosphorylation of other sites on the ability of Pak3 or Src to phosphor-
ylate S338 or Y341, respectively. Peptides were chemically phosphorylated on selected residues and used for in vitro kinase assays with
recombinant Pak3 or immunoprecipitated active Src, as described in Fig. 1. Results shown are the means of four separate experiments.
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not contribute to the substrate recognition of the site by either
protein kinase. We conclude that the apparent cooperation
between Pak and Src in Raf-1 activation in cells is not a
consequence of enhancing the recognition site of either kinase
by prior phosphorylation. Remaining possibilities include in-
direct enhancement of phosphorylation of S338 or Y341, or
simply cooperating activation mechanisms.
3.5. Phosphorylation of Raf-1 by Pak3 and Src in cells
To further address this question, we examined the relative
phosphorylation state of S338 in Raf-1 activated in COS-7
cells. Using phospho-speci¢c antisera, Raf-1 phosphorylation
in COS-7 cells was examined at S338, or S338/Y341 together.
Expression of constitutive Pakca resulted in increased S338
phosphorylation (Fig. 4A). However, when Raf-1 was co-
transfected with Pakca and Srcca, a marked increase in S338
phosphorylation was observed above that seen with Pakca
alone. This was also coincident with a large increase in dual
phosphorylation of S338/Y341 (Fig. 4B). Increased dual S338/
Y341 phosphorylation was also observed with expression of
Fig. 4. Analysis in COS-7 cells of the phosphorylation of S338 and Y341 in Raf-1 by Pak3 and Src. COS-7 cells were transiently transfected
with FLAG-tagged Raf-1 and di¡erent Pak3 and Src constructs. Lysates were generated from cells by the process described in Fig. 3. Phos-
phorylated Raf-1 species were immunoprecipitated with antisera speci¢c for phospho-S338 (A) or phospho-S338/phospho-Y341 (B). The pres-
ence of FLAG epitope in the immunoprecipitates was measured by Western blotting and levels were normalized to the total expression of
FLAG-tagged Raf-1, to give the relative levels of phosphorylation depicted in the graphs. Speci¢city of each antiserum was checked by the
manufacturer and each was found not to have any signi¢cant cross-reactivity with inappropriate phosphopeptides.
FEBS 24852 14-5-01
A.J. King et al./FEBS Letters 497 (2001) 6^14 11
Srcca alone, however in this case S338 phosphorylation re-
mained constant (Fig. 4B). Transfection of Pakdn alone dra-
matically decreased S338 phosphorylation, as expected. Ex-
pression of Srcdn signi¢cantly decreased the basal level of
phospho-S338 in Raf-1 but was less e⁄cient at interfering
with S338 phosphorylation by Pakca. We were unable to re-
producibly measure phospho-Y341 levels. These data suggest
that Src can promote Raf-1 phosphorylation on S338 by Pak
in cells, possibly by increasing Pak activity or indirectly pro-
moting access of the site to Pak for phosphorylation.
3.6. Src stimulates Pak3 activity in COS-7 cells
To observe the ability of Src to activate Pak in cells, Srcca
and Srcdn were co-expressed with wild type Pak3 and Pak3ca
in COS-7 cells. The HA-tagged Pak3 proteins were immuno-
precipitated and assayed for relative activity using the Raf-1
peptide substrate (Fig. 5). The high constitutive activity was
not altered by Srcca, indicating that the activity of Pak3ca was
independent of Srcca activity. However, Srcdn was able to at-
tenuate Pakca activity, reducing the activity associated with
the Pak3ca immunoprecipitate by 36%. This ¢nding would
indicate that Src activity is able to modulate Pak3 activity.
The failure of Srcca to further increase Pak3ca activity may
re£ect the possibility that, under the conditions of the experi-
ment, Pak3ca was already maximally activated. In contrast,
Pak3wt immunoprecipitates contained no signi¢cant activity,
being no better than the vector or Srcca alone controls. Most
signi¢cant though, Srcca dramatically stimulated Pak3wt activ-
ity. In the absence of Srcca, Pak3wt activity was undetectable
and equal to the vector control immunoprecipitate. Srcca-
stimulated Pak3wt activity was approximately 10% of the ac-
tivity measured in the Pak3ca immunoprecipitates. This in-
crease in Pak3wt activity, however, was not due to di¡erences
in Pak3wt expression since Pak3wt levels were similar under
both sets of conditions (data not shown). This observation,
in conjunction with the observation that Srcdn is able to at-
tenuate Pak3ca activity, provides evidence that Src can mod-
ulate Pak3 activity in cells.
The small increase in Pak3wt activity detected in the pres-
ence of Srcdn is likely an artifact and was equal to the back-
ground cpm obtained in immunoprecipitates from cells ex-
pressing Srcdn alone (data not shown).
4. Discussion
Regulation of Raf-1 has proven to be extremely complex
and involves interaction with many regulatory and accessory
proteins [1,3^6]. Since Raf-1 ultimately in£uences many cellu-
lar targets that control cell growth, division and di¡erentia-
tion [25^27], this kinase must be tightly regulated. The rela-
Fig. 5. Src stimulates Pak3 activity. HA-tagged Pak3 was immuno-
precipitated from COS-7 cells transiently expressing the indicated
Src and Pak3 constructs. The activity of the Pak3 in the immuno-
precipitates was measured using the Raf-1 peptide substrate. Pak3
activity is expressed as Q-32P incorporation (cpm). The data are rep-
resentative of two independent experiments performed in quadrupli-
cate.
Fig. 6. Substrate sequence determinants for phosphorylation of Raf-
1 on S338 by Pak3 and Y341 by Src. The linear sequence for Raf-1
residues 333^345 is displayed above the residues found to be most
critical for phosphorylation of the sites designated pS and pY by re-
combinant Pak3 and immunoprecipitated Src. Smaller font size indi-
cates only a moderate contribution for the designated residue in
substrate recognition.
Fig. 7. Model showing the interplay between di¡erent receptor-acti-
vated pathways that signal through Raf-1. Precise biological out-
comes are ultimately de¢ned by the level of Raf-1 activation, which
itself is represented by the weight of each arrow from Raf-1 to
Mek. The degree of activation is a manifestation of the phosphory-
lation of Raf-1 in the S338-Y341 region of its CR3 domain.
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tionship between protein phosphorylation and activity regula-
tion has been shown [28] and the multitude of post-transla-
tional modi¢cations that are witnessed in Raf-1 regulation
help provide this control [1]. We recently demonstrated S338
to be critical for Raf-1 activation in response to certain bio-
logical stimuli [9,10]. Pak was subsequently shown to phos-
phorylate S338 [13] as a consequence of signaling through
phosphatidylinositol 3-kinase [14,15]. Here, we describe ad-
vances in understanding Raf-1 S338 and Y341 phosphoryla-
tion as well as cooperativity between Pak and Src in the reg-
ulation of Raf-1.
Substitution analysis of residues surrounding Raf-1 S338
showed that certain residues strongly in£uence Pak3-mediated
phosphorylation (Fig. 6). Recognition of the S338 substrate
sequence is strongly in£uenced by the presence of positively
charged arginines at 333 (P35 position) and 336 (P32), an
aromatic residue at 340 (P+2) and negatively charged gluta-
mic acids at 343 (P+5) and 345 (P+7). This is in general
agreement with other studies for Pak2 [17,20] and Pak1 [21],
where arginines between P32 and P35 have been implicated
in enhancing phosphorylation. The negative charges at P+5
and P+7 were only found to be important in context of the
intact protein as a double glutamine substitution and may
re£ect a more gross structural e¡ect. Loss of W342 (P+4)
also reduced Pak phosphorylation of S338 in the intact CR3
protein but not in the peptide. In addition we learned that the
presence of a negatively charged residue at P31 does not
in£uence substrate recognition by Pak while introduction of
an acidic residue into the P+1 or P+2 positions is not toler-
ated. Substitution of S338 with threonine rendered CR3 a
non-substrate for Pak3. This is in accord with the observation
that a Raf-1 S338T mutant is inactive and fails to be phos-
phorylated in COS-7 cells (H.B. Diaz, unpublished result).
The sequence requirement for Src recognition of the Y341
site is less dependent on speci¢c £anking residues than Pak
recognition of S338 (Fig. 6). The presence of acidic residues at
343 (P+2) and 345 (P+4) enhanced phosphorylation of Y341.
Substitution of charged and aromatic residues between the
P31 and P38 positions had no signi¢cant e¡ects on recogni-
tion of Y341 by Src. However, we did observe that the pres-
ence of acidic residues at 338 and 339 (P33 and P32) did
enhance phosphorylation of Y341. This would be predicted
based upon the biochemical observations of the dual regula-
tion of Raf-1 by Pak and Src phosphorylation.
Two closely disposed phosphorylation sites in the Raf-1
catalytic domain have been the focus of much work [6,9,10,
12^15]. The critical nature of phosphorylation of S338 and
Y341 is apparent, as a checkpoint for the progression of
Raf-1 activation in response to many mitogenic stimuli. While
S338 and Y341 reside in the Raf-1 CR3 domain, these resi-
dues are distant from the catalytic center. Their situation near
the CR3 N-terminal, close to the glycine-rich nucleotide-bind-
ing P-loop, has been compared with similar residues in the
transforming growth factor L type-1 receptor (TGFLR-1)
[12]. In TGFLR-1, phosphorylation in this region is required
for kinase activation. By comparison with B-Raf, Src and
TGFLR-1, phosphorylation of S338 and Y341 is proposed
to be structurally signi¢cant by allowing altered orientation
of the CK helix in kinase activation. Thus S338/Y341 may
represent a Raf-1 ‘action’ region, which only requires phos-
phorylation of one residue for progression of kinase activa-
tion. Thus, phosphorylation by Pak and Src may represent
di¡erent methods of achieving the same conformational
goal. Phosphorylation of S338 leads to low-level Raf-1 acti-
vation, while Y341 phosphorylation and S338/Y341 dual
phosphorylation result in dramatically increased levels of
Raf-1 activity. Structural reorganization permitted by phos-
phorylation might be more e⁄cient with increased negative
charge by dual phosphorylation of S338/Y341. This suggests
the requirement of maximal phosphorylation for full Raf-1
activation, as seen in cell-based experiments. Based on our
data set, we conclude that co-expression of constitutively ac-
tive Src and Pak do cooperate to increase the degree of Raf-1
activation, likely due to the dramatic increase in S338 phos-
phorylation. The substrate speci¢city experiments demon-
strate that prior phosphorylation of Y431 has little e¡ect on
the ability of Pak to phosphorylate Raf-1 on S338. However,
Src clearly can increase Pak3 activity in cells. Whether this is a
result of a direct activating phosphorylation on Pak3 or an
indirect activation through Rac or Cdc42 is unclear. In addi-
tion, we observed that co-expression of constitutively acti-
vated Src and Pak3 dramatically increases phosphorylation
of Raf-1 S338 even though Src is not observed to further
increase the activity of constitutively activated Pak3. Possibly,
activation of Src results in the phosphorylation and removal
of a regulatory Raf-1 binding protein which obscures the S338
binding site. These conclusions are reinforced by the opposing
e¡ects observed with the dominant-negative alleles of Pak3
and Src. While the mechanism of action of the particular
allele of Srcdn is believed to be substrate sequestration, results
obtained with Pakdn should be interpreted more loosely. This
particular Pak3 allele functions to shut down Pak activation
by binding non-productively to Rac and Cdc42 and certainly
shuts down other Rac/Cdc42-controlled pathways as well.
Unfortunately, we were unable to reliably measure tyrosine
phosphorylation of Y341 to measure the reciprocal e¡ects of
Pak activity on Y341 phosphorylation in cells.
The cooperativity observed between Pak and Src in the
regulation of Raf-1 suggests a hypothesis in which Pak-medi-
ated S338 phosphorylation provides low-level Raf-1 activa-
tion, while Src-mediated Y341 phosphorylation induces high
Raf-1 activation, in response to di¡erent stimuli. Dual phos-
phorylation of S338/Y341 would produce super-activation of
Raf-1. Pak activation of Raf-1 was relatively small compared
with that achieved by Src. Also, relative to Src alone, Pak3
only modestly increased the activation achieved by active Src.
This alludes to Raf-1 regulation over a range of activities,
which is signi¢cant since high activity promotes cell cycle
arrest and senescence, whereas low Raf activity induces pro-
liferation [25]. This is modeled in Fig. 7. The weight of arrows
indicating phosphorylation of Raf-1 represents the level of
Raf-1 activation achieved by each phosphorylation. The mod-
el shows the potential for Src family kinases to activate Raf-1,
not only by direct Y341 phosphorylation, but also by direct
regulation of Pak as well as by an additional unde¢ned mech-
anism for regulating Pak access to Raf. Di¡erent degrees of
Raf-1 activation are dependent upon the individual or combi-
nation of phosphorylation events mediated by these kinases.
Even in the absence of exogenous active Pak, active Src may
utilize endogenous active Pak in growing cells to achieve
super-activation of Raf-1. Indeed, Mason et al. [12] propose
that S338 phosphorylation may be the limiting factor in Src-
mediated activation of Raf-1 and that, conversely, Y341 phos-
phorylation may be limiting in Ras-mediated Raf-1 activation.
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The structural signi¢cance of S338/Y341 phosphorylation
may provide a point at which signals from di¡erent pathways
can feed into a common system, £owing through Raf-Mek-
Erk. However, the co-operativity between Pak and Src, lead-
ing to super-activation, might represent another tier of Raf-1
regulation. While Pak or Src alone elicit lower individual lev-
els of Raf-1 activation, further activation may be achieved in
combination. This would provide a very powerful regulatory
mechanism governing the precise level of Raf-1 activity. Since
Raf-1 ultimately in£uences a vast array of downstream tar-
gets, di¡erent levels of Raf-1 activation might be manifested
as very di¡erent biological outcomes.
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